Abstract
Translocation of gut bacterial lipopolysaccharide (LPS) is a primary driver of complications in cirrhosis. Current therapeutic strategies are largely limited to antibiotics, which carry the risk of antimicrobial resistance. This study evaluates Yaq-001, a non-absorbable, engineered carbon bead with tailored porosity, as a novel treatment for cirrhosis and acute-on-chronic liver failure (ACLF). Using in vitro assays and two rodent models—bile duct ligation (BDL) for cirrhosis and BDL-LPS for ACLF—researchers assessed organ function, systemic inflammation, and multi-omic signatures. Results demonstrated that Yaq-001 rapidly adsorbs endotoxins and bile acids without antibiotic effects. In vivo, treatment significantly improved liver injury markers, portal pressure, renal function, and survival rates. These findings provide a strong preclinical rationale for Yaq-001 as a gut-restricted therapy to prevent complications in patients with chronic liver disease.
Introduction
In advanced cirrhosis, the intestinal barrier becomes increasingly permeable, or "leaky." This allows gut-derived toxins, particularly bacterial lipopolysaccharides (LPS or endotoxins), to translocate into the portal and systemic circulation. This translocation triggers a cascade of systemic inflammation that can precipitate Acute-on-Chronic Liver Failure (ACLF), a syndrome characterized by rapid multi-organ failure (kidneys, brain, and liver) and high mortality.
Historically, clinicians have relied on antibiotics like rifaximin to manage gut bacterial load. However, long-term antibiotic use is a "double-edged sword," as it disrupts microbiome diversity and promotes the emergence of multi-drug resistant organisms. There is an urgent clinical need for a "gut-restricted" therapy that can neutralize toxins and metabolites without exerting the selective pressure of an antibiotic. Yaq-001 was developed to fill this gap as a non-absorbable "molecular sponge."
Mechanism of Action: The Engineered Carbon Bead
Yaq-001 is a synthetic activated carbon bead characterized by bimodal porosity, designed to target specific classes of toxins:
- Micropores (<2nm): Optimized to capture smaller molecules such as ammonia and bile acids.
- Meso-macropores (30-200nm): Specifically tailored to adsorb larger biologically active toxins, including LPS and inflammatory cytokines.
Unlike traditional charcoal or antibiotics, Yaq-001 does not kill bacteria. Instead, it acts as an adsorbent within the intestinal lumen, sequestering harmful byproducts before they can cross the gut barrier. The beads are completely excreted after oral administration, ensuring no systemic absorption of the carbon itself.
Methodology
The study employed a comprehensive experimental workflow to validate the efficacy and safety of Yaq-001:
- In Vitro Characterization: Adsorption kinetics were measured for albumin, myoglobin, and endotoxins. Growth kinetics of E. coli and S. aureus were monitored to confirm the absence of antibiotic activity.
- In Vivo Rodent Models:
- Cirrhosis Model: Rats underwent Bile Duct Ligation (BDL) for four weeks to simulate chronic liver injury.
- ACLF Model: BDL rats were given a "second hit" of LPS to trigger acute failure.
- Multi-Omics Analysis: To capture the systemic impact of a gut-restricted treatment, the team performed:
- Transcriptomics: Gene expression profiling in the liver, kidney, brain, and colon.
- Microbiome Sequencing: 16S rRNA analysis of fecal samples.
- Metabolomics: Urinary $^1$H-NMR signatures to track metabolic shifts.
Key Results
Improved Survival and Organ Function
In the ACLF model, Yaq-001 treatment significantly improved survival and delayed the time to coma. In the chronic BDL models, treated animals showed marked improvements in several clinical markers:
- Liver Injury: Significant reduction in Alanine Aminotransferase (ALT) and liver cell death.
- Hemodynamics: A notable decrease in portal pressure, which is the primary driver of variceal bleeding and ascites in cirrhosis.
- Renal and Neurological Health: Treated rats exhibited lower plasma creatinine (improved kidney function) and reduced brain water (decreased edema).
Systemic Inflammation and the "Distant Organ" Effect
One of the study's most striking findings was that a treatment confined to the gut could modulate gene expression in distant organs. Transcriptome analysis revealed the downregulation of pro-inflammatory pathways (such as TLR signaling and cytokine-receptor interactions) in the liver, kidneys, and brain. This confirms that the "gut-liver axis" is part of a broader "gut-multi-organ axis" where intestinal health dictates systemic inflammatory tone.
Microbiome and Metabolomic Rebalancing
Rather than depleting the microbiome, Yaq-001 appeared to foster a more favorable microbial environment. Treatment was associated with a reduction in pro-inflammatory taxa, such as the Porphyromonadaceae family and Barnesiella genus. Furthermore, a reduction in D-lactate levels suggested improved intestinal barrier integrity, likely because the removal of luminal toxins allowed the gut lining to recover.
Discussion and Clinical Significance
The significance of this study lies in its demonstration of a non-antibiotic approach to managing bacterial translocation. By rapidly adsorbing endotoxins (60% adsorption within 30 minutes in vitro) and ammonia, Yaq-001 prevents the "priming" of immune cells like Kupffer cells in the liver. This reduction in immune sensitivity prevents the hyper-inflammatory response that typically leads to organ failure in ACLF.
While rodent models do not perfectly replicate the human microbiome, the consistency of the results across transcriptomic, metabolomic, and physiological data provides a robust foundation for human trials. Future research will need to ensure that long-term use of these beads does not inadvertently adsorb essential micronutrients, though no negative impact on animal weight or nutrition was observed in this study.
Conclusion
Yaq-001 represents a potential "first-in-class" therapy for cirrhosis. By acting as a selective adsorbent in the gut, it addresses the root cause of systemic inflammation without the risks associated with chronic antibiotic use. These preclinical data provide a strong rationale for proceeding to clinical trials aimed at preventing complications and improving survival in patients with chronic liver disease.
Summary updated